Tearsheet
Investment Highlights Market Valuation Price Chart Business Description Interactive Breakdown Latest Trefis Analyses Better Bets vs. BMY Recent Active Movers More From Trefis Peer Financials Peer Growth & Margins Peer Valuation Peer Returns Peer Analyses FDIC Bank Data Financials Segment Financials Price Behavior Short Interest Earnings Returns History SEC Filings Insider Activity Industry Resource Links External Quote Links

Bristol-Myers Squibb (BMY)

Market Price (9/17/2025): $46.32 | Market Cap: $94.1 Bil
Sector: Health Care | Industry: Pharmaceuticals

Bristol-Myers Squibb (BMY)

Market Price (9/17/2025): $46.32
Market Cap: $94.1 Bil
Sector: Health Care
Industry: Pharmaceuticals

Investment Highlights

0 Attractive yield
Total YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 11%, Dividend Yield is 5.2%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 6.5%, FCF Yield is 14%		 Weak multi-year price returns
2Y Excs Rtn is -65%, 3Y Excs Rtn is -88%		 Weak revenue growth
Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is 0.5%, Rev Chg QQuarterly Revenue Change % is -5.6%
1 Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 30%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 27%, CFO LTM is 14 Bil, FCF LTM is 13 Bil		  
2 Low stock price volatility
Vol 12M is 30%		  
0 Attractive yield
Total YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 11%, Dividend Yield is 5.2%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 6.5%, FCF Yield is 14%
1 Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 30%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 27%, CFO LTM is 14 Bil, FCF LTM is 13 Bil
2 Low stock price volatility
Vol 12M is 30%
3 Weak multi-year price returns
2Y Excs Rtn is -65%, 3Y Excs Rtn is -88%
4 Weak revenue growth
Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is 0.5%, Rev Chg QQuarterly Revenue Change % is -5.6%

Market Valuation

 9/17/252024202320222021
Share Price CYE$46.32$55.34$47.79$64.71$54.38
Market Cap CYE ($ Bil)94.1112.396.9136.5119.8
Total Debt ($ Bil)51.251.241.540.745.6
Total Cash ($ Bil)11.810.912.39.317.2
Enterprise Value ($ Bil)133.5163.5138.4177.2165.4
Valuation Ratios     
P/S TTM2.02.42.43.33.0
P/EBIT TTM11.6-17.811.117.114.7
P/E TTM17.4-12.813.224.219.8
Sector Ratios     
P/S TTM (Sector)3.73.64.14.57.3
P/EBIT TTM (Sector)-1.6-1.3-1.4-1.3-2.9
P/E TTM (Sector)-1.8-1.5-1.5-1.3-2.9
 9/17/2520242023
Share Price CYE$46.32$55.34$47.79
Market Cap CYE ($ Bil)94.1112.396.9
Total Debt ($ Bil)51.251.241.5
Total Cash ($ Bil)11.810.912.3
Enterprise Value ($ Bil)133.5163.5138.4
Valuation Ratios   
P/S TTM2.02.42.4
P/EBIT TTM11.6-17.811.1
P/E TTM17.4-12.813.2
Sector Ratios   
P/S TTM (Sector)3.73.64.1
P/EBIT TTM (Sector)-1.6-1.3-1.4
P/E TTM (Sector)-1.8-1.5-1.5

Market Cap Chart

Business Description

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. Show more

Price Returns Compared

Expand for Detailed View

 202020212022202320242025Total [1]
Returns
BMY Return0%3%19%-26%16%-16%-12%
Peers Return12%39%8%10%1%-1%82%
S&P 500 Return16%27%-19%24%23%12%104%

[1] Cumulative total returns since the beginning of 2020
[2] Peers: LLY, JNJ, MRK, ZTS, PFE. See BMY Returns vs. Peers.
[3] 2025 data is for the year up to 9/16/2025 (YTD)

Interactive Breakdown

Bristol-Myers Squibb Interactive Breakdown Analysis

Better Bets than Bristol-Myers Squibb (BMY)

 BMYBetter Performance than BMY
MetricValueIndustry (Pharmaceuticals)
Rev Chg LTM4.6%LLY (36.8%), JNJ (4.7%), PFE (13.5%), ZTS (5.3%), CORT (25.7%)
Rev Chg 3Y Avg0.5%LLY (23.4%), JNJ (4.0%), MRK (3.7%), ZTS (5.5%), JAZZ (5.5%)
Op Mgn LTM16.5%LLY (43.0%), JNJ (24.5%), MRK (31.2%), PFE (26.1%), ZTS (37.5%)
CFO/Rev LTM30.0%ZTS (31.2%), JAZZ (32.2%), ALKS (34.6%), INVA (54.2%), SIGA (66.3%)
FCF/Rev LTM27.5%JAZZ (30.3%), ALKS (31.9%), SUPN (27.9%), INVA (53.1%), COLL (28.5%)
Total Yield11.0%MRK (12.0%), PFE (13.3%), OGN (34.5%), SIGA (12.8%), EBS (32.9%)
 BMYBetter Performance than BMY
MetricValueAll Other Sectors
Rev Chg LTM4.6%NVDA (71.6%), MSFT (14.9%), AAPL (6.0%), GOOGL (13.1%), AMZN (10.9%)
Rev Chg 3Y Avg0.5%NVDA (92.0%), MSFT (12.5%), AAPL (1.8%), GOOGL (10.2%), AMZN (11.3%)
Op Mgn LTM16.5%NVDA (58.1%), MSFT (45.6%), AAPL (31.9%), GOOGL (32.7%), META (42.9%)
CFO/Rev LTM30.0%NVDA (46.6%), MSFT (48.3%), GOOGL (36.0%), META (56.4%), AVGO (42.4%)
FCF/Rev LTM27.5%NVDA (43.6%), META (30.7%), AVGO (41.6%), V (56.8%), MA (49.2%)
Total Yield11.0%BABA (38.9%), TM (2104.3%), VZ (16.0%), TD (15.6%), CMCSA (16.9%)

Latest Trefis Analyses

TitleTopicDate
0DASHBOARDS  
1Bristol-Myers Squibb Earnings Notes  
2Bristol-Myers Squibb vs Duke Energy: Which Is A Better Investment?Counter-Intuitive Comparisons 
3Bristol-Myers Squibb vs Royalty Pharma: Which Is A Better Investment?Counter-Intuitive Comparisons 
4Bristol-Myers Squibb vs Innoviva: Which Is A Better Investment?Counter-Intuitive Comparisons 
5How Does BMY Stack Up Against Its Peers?Peer Comparison 
6Better Bet Than BMY Stock: Pay Less Than Bristol-Myers Squibb To Get More From DUK, HCA   
7Better Bet Than BMY Stock: Pay Less Than Bristol-Myers Squibb To Get More From HCA, UTHR   
8Will You Be Comfortable Buying Bristol-Myers Squibb Stock?Return 
9Day 6 of Loss Streak for Bristol-Myers Squibb Stock with -12% Return (vs. -22% YTD) [7/31/2025]Notification 
10Bristol-Myers Squibb vs. Out Of Favor Health Care Stocks: Which Is A Better Investment?Investment Theme Comparisons 
11ARTICLES  
12BMY Stock Down -12% after 6-Day Loss Streak August 1st, 2025
13Is It Time To Buy Bristol Myers Squibb Stock? April 28th, 2025
14How Will Bristol Myers Squibb Stock React To Its Upcoming Earnings? April 22nd, 2025
15Is Bristol-Myers Squibb Stock A Safe Haven During Tariff Turmoil? April 4th, 2025
16Why Bristol Myers Squibb Stock Didn’t Ride The Market Wave? March 4th, 2025
Title
0DASHBOARDS
1BMY Stock Down -12% after 6-Day Loss Streak
2Is It Time To Buy Bristol Myers Squibb Stock?
3How Will Bristol Myers Squibb Stock React To Its Upcoming Earnings?
4Is Bristol-Myers Squibb Stock A Safe Haven During Tariff Turmoil?
5Why Bristol Myers Squibb Stock Didn’t Ride The Market Wave?
6ARTICLES
7Bristol-Myers Squibb Earnings Notes
8Bristol-Myers Squibb vs Duke Energy: Which Is A Better Investment?
9Bristol-Myers Squibb vs Royalty Pharma: Which Is A Better Investment?
10Bristol-Myers Squibb vs Innoviva: Which Is A Better Investment?
11How Does BMY Stack Up Against Its Peers?
12Better Bet Than BMY Stock: Pay Less Than Bristol-Myers Squibb To Get More From DUK, HCA 
13Better Bet Than BMY Stock: Pay Less Than Bristol-Myers Squibb To Get More From HCA, UTHR 
14Will You Be Comfortable Buying Bristol-Myers Squibb Stock?
15Day 6 of Loss Streak for Bristol-Myers Squibb Stock with -12% Return (vs. -22% YTD) [7/31/2025]
16Bristol-Myers Squibb vs. Out Of Favor Health Care Stocks: Which Is A Better Investment?

Recent Active Movers

1 Week Top Gainers

#TickerCompany1W RtnYTD Rtn
1BDSXBiodesix1313.2%-78.6%
2CLSDClearside Biomedical954.0%-74.9%
3SDOTSadot624.1%-79.4%
4WLDSWearable Devices498.0%-30.0%
5CHEKCheck-Cap285.6%154.6%
6ATCHAtlasClear275.9%-91.0%
7HSDTHelius Medical Technologies262.5%-95.6%
8OPIOffice Properties Income Trust261.7%-13.4%
9FGIFGI Industries156.8%145.2%
10AIREReAlpha Tech154.0%-56.1%

1 Week Top Losers

#TickerCompany1W RtnYTD Rtn
1NAKAKindly MD-81.4% 
2ATYRaTyr Pharma-79.7%-70.2%
3LGCLLucas GC-73.6%-77.1%
4EPSMEpsium Enterprise-70.1% 
5BNGOBionano Genomics-59.4%-89.7%
6FAASDigiAsia-58.5%-87.2%
7QMMMQMMM-57.5%6775.0%
8VCIGVCI Global-56.9%-99.1%
9YYGHYY-56.6%-78.5%
10XAGELongevity Health-55.5%-86.1%

1 Month Top Gainers

#TickerCompany1M RtnYTD Rtn
1PMIPicard Medical11963.5%11963.5%
2GIBOGIBO9734.4% 
3CHSNChanson International7565.0%-99.3%
4LNZALanzaTech Global7287.5%-86.0%
5QMMMQMMM3031.7%6775.0%
6OESXOrion Energy Systems1497.9%22.9%
7CURXCuranex Pharmaceuticals1401.6%1401.6%
8ENTOEntero Therapeutics565.6%117.6%
9PTNMPitanium553.2% 
10WLDSWearable Devices449.5%-30.0%

1 Month Top Losers

#TickerCompany1M RtnYTD Rtn
1CJETChijet Motor-92.2%-95.0%
2STFSStar Fashion Culture-92.2%-97.8%
3ELPWElong Power-91.6%-76.7%
4NXTTNext Technology-89.6%-95.1%
5NAKAKindly MD-89.0% 
6BINIBollinger Innovations-88.9%-100.0%
7JEM707 Cayman-88.4%-98.2%
8YAASYouxin Technology-82.5%-98.3%
9NEONNeonode-82.0%-50.2%
10NVNOenVVeno Medical-81.5%-69.8%

Recent Active Movers

1 Week Top Gainers

#TickerCompany1W RtnYTD Rtn
1BDSXBiodesix1313.2%-78.6%
2CLSDClearside Biomedical954.0%-74.9%
3SDOTSadot624.1%-79.4%
4WLDSWearable Devices498.0%-30.0%
5CHEKCheck-Cap285.6%154.6%
6ATCHAtlasClear275.9%-91.0%
7HSDTHelius Medical Technologies262.5%-95.6%
8OPIOffice Properties Income Trust261.7%-13.4%
9FGIFGI Industries156.8%145.2%
10AIREReAlpha Tech154.0%-56.1%

1 Week Top Losers

#TickerCompany1W RtnYTD Rtn
1NAKAKindly MD-81.4% 
2ATYRaTyr Pharma-79.7%-70.2%
3LGCLLucas GC-73.6%-77.1%
4EPSMEpsium Enterprise-70.1% 
5BNGOBionano Genomics-59.4%-89.7%
6FAASDigiAsia-58.5%-87.2%
7QMMMQMMM-57.5%6775.0%
8VCIGVCI Global-56.9%-99.1%
9YYGHYY-56.6%-78.5%
10XAGELongevity Health-55.5%-86.1%

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons for Bristol-Myers Squibb

Financials

BMYLLYJNJMRKZTSPFEMedian
NameBristol-.Eli LillyJohnson .Merck Zoetis Pfizer  
Mkt Price46.34764.71176.4681.09147.4623.90114.28
Mkt Cap94.1686.6424.6203.565.6135.9169.7
Rev LTM47,63653,25890,62763,6169,38563,83358,437
Op Inc LTM7,87022,88222,22819,8213,52016,66318,242
FCF LTM13,086-5016,39714,7222,21912,43812,762
FCF 3Y Avg12,225-15616,92612,8991,8699,30410,765
CFO LTM14,31010,93823,02818,5342,92915,18814,749
CFO 3Y Avg13,4197,23022,24816,7662,54912,58413,002

Growth & Margins

BMYLLYJNJMRKZTSPFEMedian
NameBristol-.Eli LillyJohnson .Merck Zoetis Pfizer  
Rev Chg LTM4.6%36.8%4.7%1.8%5.3%13.5%5.0%
Rev Chg 3Y Avg0.5%23.4%4.0%3.7%5.5%-12.4%3.8%
Rev Chg Q-5.6%37.6%5.8%-1.9%4.2%10.3%5.0%
QoQ Delta Rev Chg LTM-1.4%8.7%1.5%-0.5%1.1%2.2%1.3%
Op Mgn LTM16.5%43.0%24.5%31.2%37.5%26.1%28.6%
Op Mgn 3Y Avg17.3%35.6%26.3%22.6%36.6%20.2%24.4%
QoQ Delta Op Mgn LTM4.3%1.8%-0.2%-0.8%0.5%1.8%1.1%
CFO/Rev LTM30.0%20.5%25.4%29.1%31.2%23.8%27.3%
CFO/Rev 3Y Avg28.9%17.8%25.7%27.2%28.7%18.8%26.5%
FCF/Rev LTM27.5%-0.1%18.1%23.1%23.6%19.5%21.3%
FCF/Rev 3Y Avg26.4%0.5%19.6%20.9%21.0%13.8%20.2%

Valuation

BMYLLYJNJMRKZTSPFEMedian
NameBristol-.Eli LillyJohnson .Merck Zoetis Pfizer  
Mkt Cap94.1686.6424.6203.565.6135.9169.7
P/S2.012.94.73.27.02.13.9
P/EBIT11.638.615.110.018.610.213.3
P/E17.449.818.712.425.112.618.1
P/CFO6.662.818.411.022.48.914.7
Total Yield11.0%2.7%8.2%12.0%5.3%13.3%9.6%
Dividend Yield5.2%0.7%2.8%3.9%1.3%5.3%3.4%
FCF Yield 3Y Avg12.4%0.1%4.5%5.1%2.5%5.7%4.8%
D/E0.50.10.10.20.10.40.1
Net D/E0.40.10.10.10.10.40.1

Returns

BMYLLYJNJMRKZTSPFEMedian
NameBristol-.Eli LillyJohnson .Merck Zoetis Pfizer  
1M Rtn-4.3%9.1%0.6%-2.8%-4.3%-4.9%-3.5%
3M Rtn-1.9%-3.1%16.7%4.6%-8.5%1.3%-0.3%
6M Rtn-21.8%-6.6%9.2%-12.7%-9.7%-5.8%-8.2%
12M Rtn-4.2%-16.6%9.1%-28.7%-23.2%-14.9%-15.8%
3Y Rtn-27.4%153.9%15.4%1.1%-3.3%-38.8%-1.1%
1M Excs Rtn-6.8%6.6%-1.8%-5.2%-6.7%-7.4%-6.0%
3M Excs Rtn-14.3%-14.6%5.0%-8.4%-19.5%-9.9%-12.1%
6M Excs Rtn-38.3%-23.3%-6.3%-29.2%-26.5%-21.3%-24.9%
12M Excs Rtn-18.8%-35.7%-7.4%-44.6%-39.8%-30.4%-33.0%
3Y Excs Rtn-88.4%84.4%-45.8%-60.1%-69.9%-103.5%-65.0%

Comparison Analyses

Financials

$ Mil | FY: 12/312025Q12024Q42024Q32024Q22024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q2
Period End3/31/202512/31/20249/30/20246/30/20243/31/202412/31/20239/30/20236/30/20233/31/202312/31/20229/30/20226/30/2022
Filing Date4/24/20252/12/202510/31/20247/26/20244/25/20242/13/202410/26/20237/27/20234/27/20232/14/202310/26/20227/27/2022
Key Financials Quarterly            
Total Revenue11,20112,34211,89212,20111,86511,47710,96611,22611,33711,40611,21811,887
Ebitda4,4772,5514,7734,403-8,5594,4544,8524,5735,4874,6745,0964,854
Operating Income3,4975102,1721,6911,5141,9031,9591,9012,4321,6942,0992,642
Net Income2,456721,2111,680-11,9111,7621,9282,0732,2622,0221,6061,421
EPS1.210.040.600.83-5.890.870.940.991.080.960.750.67
Key Financials TTM            
Total Revenue TTM47,63648,30047,43546,50945,53445,00644,93545,18745,84846,15946,73847,144
Ebitda TTM16,2043,1685,0715,1505,32019,36619,58619,83020,11119,22119,30719,423
Operating Income TTM7,8705,8877,2807,0677,2778,1957,9868,1268,8679,1049,7509,670
Net Income TTM5,419-8,948-7,258-6,541-6,1488,0258,2857,9637,3116,3276,6776,617
Growth Rates Quarterly            
Total Revenue Growth-5.6%7.5%8.4%8.7%4.7%0.6%-2.2%-5.6%-2.7%-4.8%-3.5%1.6%
EBITDA Growth152.3%-42.7%-1.6%-3.7%-256.0%-4.7%-4.8%-5.8%19.4%-1.8%-2.2%5.6%
Operating Income Growth131.0%-73.2%10.9%-11.0%-37.7%12.3%-6.7%-28.0%-8.9%-27.6%4.0%12.7%
Net Income Growth120.6%-95.9%-37.2%-19.0%-626.6%-12.9%20.0%45.9%77.0%-14.8%3.9%34.7%
Margins Quarterly            
EBITDA Margin40.0%20.7%40.1%36.1%-72.1%38.8%44.2%40.7%48.4%41.0%45.4%40.8%
Operating Income Margin31.2%4.1%18.3%13.9%12.8%16.6%17.9%16.9%21.5%14.9%18.7%22.2%
Net Income Margin21.9%0.6%10.2%13.8%-100.4%15.4%17.6%18.5%20.0%17.7%14.3%12.0%
Cash & Debt            
Total Cash11,78210,8598,0946,6539,67012,2807,6858,7309,2699,2539,02713,266
Total Debt51,23951,20051,40054,00457,40941,46439,26739,18639,37140,71740,11043,042
Net Debt / (Cash)39,45740,34143,30647,35147,73929,18431,58230,45630,10231,46431,08329,776
Cash Flows Quarterly            
FCF from Operations1,9544,4395,5912,3262,8344,2524,7511,8872,9703,3063,6872,261
Cash Flows TTM            
FCF from Operations TTM14,31015,19015,00314,16313,72413,86012,91411,85012,22413,06613,81715,396
Returns to Shareholders Quarterly            
Dividends1,2581,2181,2161,2171,2121,1601,1911,1971,1961,1451,1541,150
Share Repurchases-0-0-0-0-0-04,0009052502,416585-0
Return on Invested Capital (ROIC) Quarterly            
ROIC29.4%2.2%14.5%14.3%12.7%26.1%22.5%25.0%26.4%21.5%19.7%25.9%
Return on Invested Capital (ROIC) TTM            
ROIC TTM17.8%14.6%16.8%14.9%15.2%26.7%24.3%24.5%24.5%23.8%27.2%28.1%

Segment Financials

Revenue by Segment

$ Mil20242023202220212020
Eliquis12,20611,78910,7629,1687,929
Opdivo9,0098,2497,5236,9927,204
Revlimid6,0979,97812,82112,1061,299
Orencia3,6013,4643,3063,1572,977
Pomalyst/Imnovid3,4413,4973,3323,070322
Yervoy2,2382,1312,0261,6821,489
Sprycel1,9302,1652,1172,1402,110
Other Growth products1,2111,092   
Reblozyl1,008717551274 
Abraxane1,0048111,1811,247166
Other Legacy products9621,162   
Opdualag6272520  
Abecma472388164  
Zeposia43425013412 
Breyanzi36418287  
Camzyos231240  
Sotyktu17080  
Augtyro100  
Cobenfy00   
Krazati00   
Inrebic  74555
Mature and other brands  2,2342,217 
Onureg  7317 
Empliciti   381357
Baraclude    555
Other Brands    1,674
Vidaza    58
Total45,00646,15946,38542,51826,145


Price Behavior

BMY Betas & Captures as of 8/31/2025

 1M2M3M6M1Y3Y
Beta-0.120.630.630.380.270.30
Up Beta0.340.500.200.170.080.21
Down Beta-1.18-1.53-0.130.500.410.32
Up Capture57%106%68%24%22%6%
Bmk +ve Days10223571142415
Stock +ve Days13223266136371
Down Capture-96%181%151%82%51%72%
Bmk -ve Days11192754106334
Stock -ve Days8193059112374

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

Short Interest

Short Interest: As Of Date8292025
Short Interest: Shares Quantity31,193,823
Short Interest: % Change Since 81520255.1%
Average Daily Volume9,732,383
Days-to-Cover Short Interest3.21
Basic Shares Quantity2,031,000,000
Short % of Basic Shares1.5%

Returns Analyses

Earnings Returns History

Expand for More

 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
7/31/2025-5.8%-2.5%2.0%
4/24/20250.3%3.4%-3.1%
2/6/2025-3.8%-6.0%2.3%
10/31/20245.9%5.0%12.5%
7/26/202411.4%6.4%6.3%
4/25/2024-8.5%-9.5%-15.0%
2/2/20240.1%0.1%4.6%
10/26/2023-6.4%-9.4%-12.1%
...
SUMMARY STATS   
# Positive121312
# Negative121112
Median Positive2.0%3.4%2.1%
Median Negative-3.4%-2.6%-3.2%
Max Positive11.4%6.8%12.5%
Max Negative-8.5%-9.5%-15.0%

SEC Filings

Expand for More

Report DateFiling DateFiling
6302025731202510-Q 6/30/2025
3312025424202510-Q 3/31/2025
12312024212202510-K 12/31/2024
93020241031202410-Q 9/30/2024
6302024726202410-Q 6/30/2024
3312024425202410-Q 3/31/2024
12312023213202410-K 12/31/2023
93020231026202310-Q 9/30/2023
6302023727202310-Q 6/30/2023
3312023427202310-Q 3/31/2023
12312022214202310-K 12/31/2022
93020221026202210-Q 9/30/2022
6302022727202210-Q 6/30/2022
3312022429202210-Q 3/31/2022
12312021209202210-K 12/31/2021
93020211027202110-Q 9/30/2021

Insider Activity

Expand for More

 OwnerTitleFiling DateActionPriceSharesTransacted
Value		Value of
Held Shares		Form
0Hickey BenjaminPresident, RayzeBio Org.5132025Sell38.01973,702 Form
1Hirawat SamitEVP,Chief Med.Offr.,Drug Dev.4292025Buy47.584,250202,2153,973,572Form
2BOERNER CHRISTOPHER S.Chief Executive Officer2212025Buy55.052,000110,0965,759,452Form
3Hirawat SamitEVP,Chief Med.Offr.,Drug Dev.2192025Buy54.841,823100,0003,506,058Form
4Holzer Phil MSVP and Controller11052024Sell55.6270038,930654,032Form

Industry Resources

External Quote Links


Prefer one of these to Trefis? Tell us why.